Figure 9.

Summary of the observed anti-fibrotic effects of pirfenidone, galunisertib, and imatinib in precision-cut kidney slices (PCKS) and human renal fibroblasts (HRFs). Blue color indicates a significant inhibition, red color shows significant increase, and markers that were not tested in any particular condition are colored in grey. Numbers represent mean percent reduction in gene or protein expression that did not reach statistical significance (only reduction ≥20% is taken into account). Concentration-dependent effects of tested compounds are illustrated in Figure S6 (PCKS) and Figure S9 (HRFs). Annotations: mPCKS, murine (healthy control) precision-cut kidney slices; fmPCKS, fibrotic murine slices prepared from obstructed for seven days (7dUUO) kidneys; hPCKS, human (healthy control) kidney slices; fhPCKS, fibrotic human slices prepared from patient diseased renal tissues.